Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is supported by an educational grant from Lexicon Pharmaceuticals, Inc.
Release Date: June 29, 2018
Expiration Date: June 29, 2019
Media: Internet - based
This activity, Oncology Briefings™: Understanding Carcinoid Syndrome Diarrhea From Diagnosis to Treatment, developed in the Physicians’ Education Resource, LLC, (PER®) established Oncology Briefings™ legacy format, is an online interactive monograph that provides an overview of recent data regarding the management of carcinoid syndrome diarrhea. This presentation features a national thought leader, Michael A. Morse, MD, who provides key insights and presents 2 patient cases with carcinoid syndrome diarrhea who were successfully treated.
Instructions for This Activity and Receiving Credit
This online CME activity is directed toward oncology healthcare professionals involved in the treatment and management of carcinoid syndrome and carcinoid syndrome diarrhea, including medical oncologists, gastroenterologists, endocrinologists, and surgical oncologists. Fellows, nurses, nurse practitioners, physician assistants, and other healthcare professionals involved in the management of patients with carcinoid syndrome are also invited to participate.
Upon completion of this activity, you should be better prepared to:
Michael A. Morse, MD, FACP, MHS
Duke University Medical Center
Disclosure: Grant/Research Support: Ipsen, Merck, BMS; Speaker’s Bureau: Novartis, Ipsen, Merck, Lexicon, Genentech, Taiho, Celgene
The staff of Physicians’ Education Resource®, LLC, (PER®) have no relevant financial relationships with commercial interests to disclose.
As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.
Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician or nurse relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.
March 7, 2019 - March 10, 2019
March 8, 2019
Cancer Summaries and Commentaries™: Update from Atlanta – Advances in the Treatment of Acute Myeloid Leukemia
Mar 30, 2019
Mar 30, 2019
Mar 30, 2019